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Background: Toxoplasma gondii is a ubiquitous protozoan intracellular parasite, the causative agent of
toxoplasmosis, and a worldwide zoonosis. Apical membrane antigen-1 (AMA1) and rhoptry neck protein (RON2,
RON4) are involved in the invasion of T. gondii.
Methods: This study chemically synthesized peptides of TgAMA1, TgRON2 and TgRON4 that contained the T- and
B-cell epitopes predicted by bioinformatics analysis. We evaluated the systemic response by proliferation, cytokine
and antibody measurements as well as the mucosal response by examining the levels of antigen-specific secretory
IgA (SIgA) in the nasal, vesical and intestinal washes obtained from mice after nasal immunization with single
(AMA1, RON2, RON4) or mixtures of peptides (A1 + R2, A1 + R4, R2 + R4, A1 + R2 + R4). We also assessed the parasite
burdens in the liver and brain as well as the survival of mice challenged with a virulent strain.
Results: The results showed that the mice immunized with single or mixed peptides produced effective mucosal
and systemic immune responses with a high level of specific antibody responses, a strong lymphoproliferative
response and significant levels of gamma interferon (IFN-γ), interleukin-2 (IL-2) and IL-4 production. These mice also
elicited partial protection against acute and chronic T. gondii infection. Moreover, our study indicated that mixtures
of peptides, especially the A1 + R2 mixture, were more powerful and efficient than any other single peptides.
Conclusions: These results demonstrated that intranasal immunisation with peptides of AMA1, RON2 and RON4
containing T- and B-cell epitopes can partly protect mice against toxoplasmosis, and a combination of peptides as
a mucosal vaccine strategy is essential for future Toxoplasma vaccine development.
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Toxoplasma gondii is a significant obligate intracellular
protozoan parasite because it infects a wide variety of
warm-blooded animals, including humans [1]. Infection
in humans can cause severe ocular, neurologic and
sometimes systemic disease, especially in immunocom-
promised and congenitally infected individuals [2-4].
Toxoplasma gondii can sometimes be acquired congeni-
tally by a newborn from an infected mother, congenital* Correspondence: guorongyin@163.com
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unless otherwise stated.toxoplasmosis may cause abortion, neonatal death or
fetal abnormalities [4,5]. Currently, T. gondii control de-
pends primarily on chemotherapy, but the available
medicines have many severe side effects. The develop-
ment of safe and effective vaccines is the best strategy to
prevent toxoplasmosis [6,7].
Successful invasion is the first and important step for
the parasite to infect the host cells. The invasion process
by T. gondii involves a moving junction (MJ) formed be-
tween the apex of the parasite and the host cell mem-
brane [4], and the MJ structure is used by T. gondii to
propel itself inside the cell using a gliding motion. Apical
membrane antigen-1 (AMA1) plays a central role duringThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 The sequences of the peptides of T/B combined



















#AMA1: Apical membrane antigen-1; RON2: Rhoptry neck protein 2; RON4:
Rhoptry neck protein 4.
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junction complex [12,13]. Rhoptry neck protein 2 (RON2)
is present not only at the nascent MJ [13] but also at the
progressing MJ, where it co-localizes with other RON
partners. Therefore, RON2 is present at the host cell-
parasite interface during the complete invasion process
[14]. AMA1 uses the RON2 as a receptor, and the AMA1-
RON2 interaction is a key for invasion [14,15]. Moreover
RON4 participates in MJ formation and is an indispens-
able component of the MJ complex [12,13,16].
Because MJ components play an essential role in inva-
sion by T. gondii, the proteins in the MJ structure may be
potential vaccine candidates. AMA1 has been a key mal-
aria vaccine candidate and induces antibodies that inhibit
invasion and confer protection in animals [11,14]. In
addition, a plasmid that encodes T. gondii AMA1 has been
shown to generate a strong specific immune response and
to provide effective protection against toxoplasmosis in
mice [17]. Experimental studies revealed RON2 as a po-
tential Plasmodium vaccine candidate [18]. Recent study
has shown that a DNA vaccination that expresses RON4
and RON4 protein (RON4S2) induced immune responses,
but failed to protect the mice against chronic toxoplasmo-
sis [19]. The all above studies showed that AMA1, RON2
and RON4 might be potential vaccine antigens against
toxoplasmosis.
Vaccine needs to include all the components capable
of eliciting a protective immune response, notably the T-
and B- cell epitopes. Attempts to develop a peptide vac-
cine that contains T- and B-cell epitopes for T. gondii
have shown encouraging results [20,21]. Since bioinfor-
matics has played a significant role in the analysis of
protein epitopes, structures and functions, we used bio-
informatics to predict the T- and B-cell epitopes of
TgAMA1, TgRON2 and TgRON4 in this study.
The natural site of T. gondii infection is the mucosal
surface of the intestine, and effective protection may re-
quire both mucosal and systemic immune responses.
The intranasal route acts as an interesting alternative
vaccination route and promoted both systemic and mu-
cosal immune responses to an antigen [22-25], which
can be used to target pathogens that invade far from the
immunization site, such as the intestines [26].
Although host cell invasion has been well described at
the ultrastructural and molecular level, the immunogenicity
and protective efficacy of AMA1, RON2 and RON4 are still
poorly understood. In this study, we predicted and synthe-
sized the peptides of AMA1, RON2 and RON4 containing
the T- and B-cell epitopes of T. gondii. We also compara-
tively evaluated the immune responses and protective effi-
cacy of a single peptide of AMA1 (A1), RON2 (R2) or
RON4 (R4), mixtures of two peptides (A1 + R2, A1 + R4 or
R2 + R4) and a mixture of three peptides (A1 + R2 + R4) in
BALB/c mice via intranasal immunization for the first time.Methods
Epitopes prediction and peptides synthesis
The secondary structure and the B cell epitopes of AMA1,
RON2 and RON4 of Toxoplasma gondii were predicted
by the bioinformatics software of the DNAStar Protean
system and the Bcepred online prediction tool [27,28].
Based on the results of these methods, we chose the
peptides that have good hydrophilicity, satisfactory
flexibility, high accessibility and strong antigenicity, but
not the α-helix and β-folded sheets, which do not easily
interact with antibodies and generally do not act as epi-
topes. We also predicted the potential B cell epitopes
of TgAMA1, TgRON2 and TgRON4 by using the DNA-
MAN v6 software [29]. We used the online service
SYFPEITHI (http://www.syfpeithi.de/bin/MHCServer.dll/
EpitopePrediction.htm) to predict the Th cell epitopes of
TgAMA1, TgRON2 and TgRON4. Based on the results
obtained with these methods, the overlap regions of the
predicted results were regarded as the potential T/B com-
bined epitopes of TgAMA1, TgRON2 and TgRON4.
The chemically synthesized peptides listed in Table 1
were obtained from a peptide specialty laboratory (China
Peptides Co., Ltd), which purified peptides by HPLC and
verified their chemical identity by mass spectrometry. The
concentrations of peptide solutions were determined via
quantitative amino acid analysis using a Biochrom 20
Amino Acid Analyzer (Pharmacia Biotech). The purity of
peptides was >98% in the lyophilized form.
Toxoplasma gondii strain
The tachyzoites of the virulent T. gondii RH strain were
used to challenge mice, and were provided by the Peking
University Health Science Center (Beijing, China). The
parasites were maintained and collected from the peri-
toneal cavity of infected specific-pathogen-free (SPF)
BALB/c mice as previously described [24,25].
Mice and ethics statement
Female BALB/c mice were purchased from the Institute
of Laboratory Animals, Chinese Academy of Medical
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under specific-pathogen-free conditions at the Centre of
Laboratory Animals with a 12-hour light/dark cycle and
provided with rodent feed and water ad libitum. The
mice were acclimated for one week prior to the experi-
ments. The animal protocols were approved by the La-
boratory Animal Use and Care Committee of Shanxi
Medical University (Permit No: SXMU-2011-16) and the
Ethics Committee on Animal Research of the Shanxi
Medical University (Protocol #: 20110320-1). All surgery
was performed under sodium pentobarbital anaesthesia,
and all possible efforts were made to minimise suffering
of experiment mice.
Immunization and challenge
A total of 176 female BALB/c mice aged 6 weeks were
randomly divided into eight groups (22 mice per group).
All mice were intranasally immunized with 30 μg AMA1,
30 μg RON2, 30 μg RON4, 15 μg AMA1 plus 15 μg
RON2 (A1 + R2), 15 μg AMA1 plus 15 μg RON4 (A1 +
R4), 15 μg RON2 plus 15 μg RON4 (R2 + R4) or a mixture
of three peptides (10 μg of each peptide, A1 + R2 + R4).
The peptides were suspended in 20 μl of sterile PBS, while
control mice received 20 μl of sterile PBS alone. Each dose
of immunogen was instilled into the nostrils of mice with
a micropipettor (10 μl /nostril). All animals were vacci-
nated three times on days 0, 14 and 21.
Two weeks after the final inoculation (on day 35), 6
mice in each group were anesthetized with sodium
pentobarbital (1.5%, 0.1 ml/20 g weight). Blood samples
were collected from the mice in each group via retro-
orbital plexus puncture, and the sera were stored at -70°C
for further analysis. The spleens were collected under
aseptic conditions to perform lymphocyte proliferation
assays, and the culture supernatants were used for cyto-
kine assays. Mucosal washes, including nasal, vesical and
intestinal washes, were collected using PBS and stored
at -70°C for secretory IgA (SIgA) assays.
Two weeks after the last immunization, another 10 mice
from each group were challenged orally (with a feeding nee-
dle) with a lethal dose (4 × 104 tachyzoites per mouse) of
T. gondii RH strain. The symptoms and survival times of
the challenged mice were monitored and recorded thrice
daily for 30 days. To evaluate the effect of the immunization
on the tissue tachyzoite burdens, the remaining 6 mice from
each group were orally challenged with a nonlethal dose
(1 × 104 tachyzoites per mouse) of T. gondii strain RH. On
the 30th day after being challenged, the mice were anesthe-
tized with sodium pentobarbital, and the numbers of tachy-
zoite in the livers and brains were measured using a
sensitive real-time quantitative PCR (qRTPCR) method as
previously described [25,30].
For mice survival analysis, the infected mice were
monitored at 8 am, 2 pm and 8 pm daily regarding theirphysical appearance, such as displaying rough coat, de-
creases in appetite, weakness/inability to obtain feed or
water and depression. When these conditions were ob-
served, a mouse would be moved to an isolated cage for
further husbandry; if obvious suffering, such as strug-
gling or whining was observed, the mouse would be
sacrificed through ether inhalation. No obvious suffering
was observed in this study.
Sera antibodies determination
Antigen-specific IgA, IgG and IgG subclasses were ana-
lyzed by enzyme-linked immunosorbent assay (ELISA)
as previously described [24]. Briefly, each well of a 96-
well microtiter plates was coated overnight at 4°C with
100 μl peptide diluted in 0.05 M carbonate buffer
(pH 9.6) at the optimal concentrations of 10 μg/ml for
the AMA1, RON2 or RON4 groups, 12 μg/ml for the
A1 + R2, A1 + R4 and R2 + R4 groups (6 μg/ml each pep-
tide) or 15 μg/ml for the A1 + R2 + R4 and control
groups (5 μg/ml each peptide). Murine sera diluted
1:300 in PBS was applied to the wells, and the plate was
incubated at 37°C for 2 h, followed by the addition of
goat anti-mouse IgG- or IgA-horseradish peroxidase
conjugated antibody as a secondary antibody (Sigma),
which was diluted 1:2000 or 1:1000. To analyze the sub-
classes, the sera were diluted 1:300, applied to the plates
and developed with goat anti-mouse IgG1- or IgG2a-
horseradish peroxidase conjugated antibody (Proteintech
Group, Inc., USA) diluted at 1:2000. The results were
expressed as OD492 using an ELISA plate reader and de-
termined in duplicate for each serum sample from at
least two independent ELISAs.
Spleen cell proliferation assay
Spleen cell proliferation was assayed as previously de-
scribed [25]. In brief, 5 × 105 cells per well were cultured
in triplicate in 96-well plates containing RPMI-1640
medium supplemented with penicillin-streptomycin
(1 mM) and 10% fetal calf serum (FCS). The culture was
stimulated with either 10 μg/ml of peptide, 5 μg/ml of
concanavalin A (Con A) as a positive control or medium
alone for proliferation. The plates were incubated in 5%
CO2 at 37°C for 4 days. Next, 10 μl of CCK-8 reagent
(Dojindo Laboratories, Japan) was added to each well,
and the plate was incubated for 3 h. The optical density
was then determined at 450 nm using an ELISA reader.
The spleen cell proliferative responses were quantitated
using a stimulation index (SI), which was calculated as
the ratio of the average OD450 of the stimulated cells to
the average OD450 of the unstimulated cells.
Spleen cell cultures and cytokine assays
Splenocyte suspensions were prepared from six mice in
each group 2 weeks after the last immunization, and
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triplicate in RPMI-1640 containing 10% FCS as de-
scribed previously [24,25]. The culture was stimulated
with 10 μg/ml peptide. The cell-free supernatants were
harvested and assayed for interleukin-2 (IL-2) and IL-4
activities at 24 h, while the IL-10 activity was assessed at
72 h and the interferon-gamma (IFN-γ) activity was
assessed at 96 h. The concentrations of IL-2, IL-4, IL-10
and IFN-γ were determined by a commercial ELISA kit
(PeproTech, USA) according to the instructions pro-
vided by the manufacturer. The sensitivity limits of de-
tection of IL-2, IL-4, IL-10 and IFN-γ were 16, 16, 47
and 23 pg/ml, respectively.
Mucosal washes collection and SIgA determination
Prior to collecting the samples, the mice were deprived
of food for 8 h to deplete the intestinal contents. Nasal
washes were collected as described previously [25,31].
Briefly, the trachea was surgically exposed. A micropip-
ette was then passed through the larynx and nasal cavity
and a total of 0.6 ml of sterile PBS was flushed five times
(0.1 ml per time) per mouse. The intestinal washes were
collected using previously described protocols [24,25,32].
The small intestine sample was washed with 3.0 ml PBS.
To collect the vesical washes, the bladder was exposed
and rinsed gently with sterile PBS using the tip of a
micropipette through the urethra. A total of 0.6 ml of
sterile PBS was flushed gently in and out of the bladder,
and all fluids were collected by micropipette. The blad-
der was flushed six times (0.1 ml per flush). Every 0.1 ml
PBS was re-aspirated into the micropipette and re-
injected into the bladder for a total of three cycles before
final withdrawal.
All mucosal washes were centrifuged at 1000 × g for
10 min at 4°C to remove any tissue, fecal matter and cellu-
lar debris and were stored at -20°C until assayed. The titers
of SIgA in the nasal, vesical and intestinal washes were also
detected by ELISA at 492 nm as described above.
Statistical analysis
The mean of each variable (IgA, total IgG, IgG1, IgG2a,
IFN-γ, IL-2, IL-4 and IL-10) was compared between the
different groups using one-way ANOVA. All statistical
analyses were performed using the SPSS software for
Windows version 13.0. The differences were considered
statistically significant at P < 0.05. The tachyzoite bur-
dens and survival times for vaccinated and control mice
were compared using the Kaplan-Meier method. Levels
of significance of the differences between groups were
determined by the Student’s unpaired t test. Two-sided
P values < 0.05 were considered to indicate statistical
significance. Tests of normality for the data within each
group were analyzed by the Shopiro-Vilk, P values
were > 0.10.Results
Sera antibodies responses
Significantly high levels of IgA were detected in the
sera from all immunized mice except the RON2 group
when compared with the controls (P < 0.05 or P < 0.01).
Among the immunized groups, the highest titer was
generated in the A1 + R2 group, which was higher
than the single peptide groups and A1 + R2 + R4 group
(P < 0.05) (Figure 1A). All mice immunized with peptides
developed higher total IgG levels, followed in order by
the A1 + R2, A1 + R4 and R2 + R4 groups, in comparison
to either control group, RON2 group or RON4 group
(P < 0.05 or P < 0.01) (Figure 1B). The distributions of
serum IgG1 and IgG2a are shown in Figure 2C. With
the exception of the levels of IgG2a of mice from the
RON2 and RON4 groups, the IgG1 and IgG2a levels of
immunized mice were significantly higher than those of
the control group (P < 0.05).
Spleen cell proliferation responses in vitro
Spleen cells from 8 groups of mice were prepared
2 weeks after the last immunization to assess the prolif-
erative responses to the peptides. As shown in Table 2,
the splenocyte stimulation indices (SI) from the immu-
nized groups were higher than that of the PBS group
(P < 0.01). A1 + R2 immunization had the strongest ac-
tivity vs all other groups. In addition, splenocytes from
each experimental and control group proliferated well in
response to the ConA (data not shown).
Cytokines production in vitro
The cell-mediated immunity produced in the immunized
mice was evaluated by measuring the amount of cyto-
kines (IFN-γ, IL-2, IL-4 and IL-10) in the supernatants
of stimulated splenocyte cultures from mice of all
groups. As shown in Table 2, significantly high levels of
IFN-γ, IL-2 and IL-4 were detected in mice from all im-
munized groups compared with the control (P < 0.05). In
addition, mice immunized with A1 + R2 had highest
levels of IFN-γ, IL-2 and IL-4 than those of the single
and mixture peptide groups (P < 0.05). However, the pro-
duction of IL-10 did not statistically differ among all
groups (P > 0.05).
SIgA production in mucosal washes
The titers of SIgA in the nasal, vesical and intestinal
washes of immunized mice were analyzed two weeks
after the last immunization. Significantly higher titers of
SIgA were detected in the mucosal washes from all im-
munized mice compared with the control (P < 0.05 or
P < 0.01). As shown in Figure 2A, the mice immunized
with peptides cocktail, especially A1 + R2, produced
higher levels of SIgA in nasal washes (P < 0.05). Among
the three single peptide groups, the highest titer was
Figure 1 Nasal immunization induces antigen-specific IgA and
IgG responses in sera. Serum samples were collected and diluted
1:300 to analyze the (A) IgA, (B) total IgG, (C) IgG1 and IgG2a
contents by ELISA 14 days after the last immunization. The results
are expressed as the means of the OD492 ± SD (n = 6) and from the
two - time determinations. a vs. b, P < 0.05; c vs. d, P <0.01.
Figure 2 Nasal immunization induces antigen-specific SIgA
responses in mucosal washes. Detection of SIgA in (A) nasal,
(B) vesical and (C) intestinal washes from immunized mice by ELISA.
Washes were obtained from six mice of each group 14 days after
the last immunization. The results are expressed as the means of the
OD492 value and standard deviation of the samples. a vs. b, P < 0.05;
c vs. d, P <0.01.
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Table 2 Lymphocyte proliferation and cytokine production by splenocytes stimulated with peptides
Groups# Lymphocyte SI## Cytokine production (pg/ml)##
IFN-γ IL-2 IL-4 IL-10
PBS 0.76 ± 0.04 a 54.96 ± 12.07 a 57.17 ± 8.64 a 67.17 ± 6.43 a 84.13 ± 6.43
AMA1 2.04 ± 0.12 c 103.09 ± 18.99 b 156.58 ± 12.47 b 147.75 ± 11.67 b 102.25 ± 14.67
RON2 2.14 ± 0.24 c 97.39 ± 13.21 b 147.33 ± 11.92 b 136.42 ± 19.22 b 100.55 ± 19.22
RON4 2.21 ± 0.19 c 94.53 ± 16.60 b 134.42 ± 16.30 b 145.58 ± 12.98 b 97.75 ± 12.98
A1 + R2 3.17 ± 0.35 c 156.62 ± 17.25 c 219.71 ± 17.11 c 190.17 ± 21.11 c 110.13 ± 11.11
A1 + R4 2.21 ± 0.31 c 116.52 ± 16.60 b 183.84 ± 14.62 c 172.08 ± 16.22 b 111.51 ± 16.22
R2 + R4, 2.24 ± 0.40 c 123.36 ± 16.21 b 165.75 ± 24.20 b 174.83 ± 41.98 b 110.81 ± 11.98
A1 + R2 + R4 2.54 ± 0.32 c 108.52 ± 21.21 b 162.34 ± 17.11 b 174.17 ± 21.11 b 109.75 ± 11.11
#n = 6 per group.
##Splenocytes from mice were harvested 2 weeks after the last immunization. SI represents stimulation index, calculated as the ratio of the OD450 of stimulated
cells to the OD450 of unstimulated cells. The values for IFN-γ were obtained at 96 h, while the values for IL-2 and IL-4 were obtained at 24 h, and the values for
IL-10 were obtained at 72 h. The results are presented as the mean ± SD of three replicate experiments. a vs b: P < 0.05; b vs c: P < 0.05; a vs c: P < 0.01.
Zhang et al. Parasites & Vectors  (2015) 8:15 Page 6 of 9generated in the AMA1 group and the lowest was
RON4 group.
The A1 +R2 immunized mice developed the highest
levels of SIgA in the vesical washes among all groups. More-
over, the level of SIgA in the vesical washes of mice immu-
nized with the three mixtures (A1 + R2 +R4) was higher
than those of the single peptide groups and the R2 + R4
group (P < 0.05) (Figure 2B). As depicted in Figure 2C, the
highest levels of SIgA were detected in the intestinal washes
of mice immunized with A1 +R2, which were significantly
higher than those of the other groups (P < 0.05 or P < 0.01).
Protection against nonlethal and lethal T. gondii infection
To evaluate the efficacy of the peptide antigens against T.
gondii infection, the numbers of tachyzoites in the livers
and brains in the mice were determined one month post-
peroral challenge. As shown in Figure 3, the tachyzoite
loads in the liver and brain of all mice immunized with
peptides were significantly lower than those in the PBS
group (P < 0.05). Furthermore, the lowest tachyzoite
loads in liver and brain were observed in the A1 + R2
group (P < 0.01); their reduction rates were 55.79% and
55.68%, respectively, when compared to the PBS group.
Additionally, the reduction among the immunized groups
did not statistically differ.
The survival rates of the mice were recorded daily fol-
lowing oral challenge for 30 days. The survival curves of
all groups of mice are shown in Figure 4. Although the
survival rate of all mice immunized with peptides were
extended compared to mice from the control group,
which died within 13 days, the survival rates of A1 + R2
(70%), AMA1 (60%), A1 + R2 + R4 (50%) and RON2
(40%) immunization reached significant level (P < 0.05).
Discussion
Epitope-based vaccines should contain both T- and B-cell
epitopes that will serve to induce proper immune responses[33]. In the present study, we focused on the AMA1,
RON2 and RON4 involved in the invasion of Toxoplasma
gondii. We predicted the potential T/B combined epi-
topes of TgAMA1, TgRON2 and TgRON4 by the bio-
informatics method and evaluated the immune responses
and protective efficacy of a single peptide or mixtures of
peptides by contrast.
As a mucosal pathogen, the natural site of T. gondii
infection is the mucosal surface where it can replicate
efficiently [34]. By taking advantage of the common mu-
cosal immune system (CMIS) [35], mucosal vaccination
can elicit immune responses in multiple mucosal ef-
fector sites that are far from the immunization site [36].
Therefore, preventing infection at these sites via mucosal
active vaccines is a promising and rational approach for
vaccine development. Intranasal immunization is an ef-
fective and safe way of providing a disseminated mucosal
immunity as well as systemic immunity [23,37].
An efficient mucosal vaccine should promote both
mucosal and systemic immune responses [35,38]. The
mucosal immune system can induce potent protective
immunity against harmful pathogens to avoid mucosal
colonization and pathogen invasion [39]. Secretory IgA
(SIgA) is the main humoral mediator of the mucosal
first-line defense system, and it is locally produced in
the effector tissues of the mucosal immune system [40].
To evaluate mucosal immune responses, the levels of
antigen-specific SIgA in the nasal, vesical and intestinal
washes of immunized mice were examined in this study.
We found a strong SIgA antibody response in the nasal
and vesical washes of mice immunized with peptides.
Moreover, the levels of SIgA in washes of mice immu-
nized with mixtures of peptides, especially the A1 + R2
mixture, were significantly enhanced compared to the
single peptide immunization. The intestinal IgA system
is the best-understood contributor to mucosal immunity.
In our study, the strongest SIgA antibody response in
Figure 4 Evaluation of survival curves against the lethal
challenge. Survival curves of immunized mice of the 8 groups
(n = 10) were monitored daily after challenge with 4 × 104 tachyzoites
of T. gondii RH strain for 30 days post-challenge.
Figure 3 Assessment of the reduction of tachyzoite loads in
liver and brain. (A) Liver and (B) brain tachyzoite burdens one
month after challenge (mean ± SD, n = 6). The tachyzoite loads
(×105/per gram tissue) in the liver and brain of mice immunized
after challenge with 1 × 104 tachyzoites of T. gondii strain RH per
mouse. The data columns in the illustration represent the reduction
(%) of tachyzoite loads in the liver and brain of mice immunized
compared with the values of the control group (PBS). The counting
of parasites has been done twice for each tissue from per mouse.
Values are means ± SD. a vs. b, P < 0.05; c vs. d, P <0.01.
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with A1 + R2. Taken together, the above results imply that
a mixture of peptides, especially the mixture of two pep-
tides (A1 + R2), was more effective in eliciting a mucosal
immune response than a single peptide. Moreover, SIgA
antibodies have been shown to reduce T. gondii infection
of human enterocytes in vitro, which suggests that SIgA
secretion is also important in defending against pathogen
invasion into the intestinal mucosa [41,42].
System immunity plays a significant role in the defense
against pathogens. Consistent with previous reports
[42,43], our results showed that mice immunized with
peptides had high specific IgG and IgA antibodies in
sera. Moreover, the reactions of IgG and IgA of miceimmunized with peptide mixtures were significantly en-
hanced compared to the single peptide immunization.
Specific antibodies seem to be important in controlling
T. gondii infection because the antibodies produced by B
cells inhibit the attachment of the parasites to the host
cell receptors, and macrophages kill intracellular Ab-
coated tachyzoites [44,45]. Additionally, the splenocyte
from the peptide immunized mice proliferated more
rapidly than those of the control group, and the mice
immunized with A1 + R2 showed the strongest increase.
Ideal vaccine candidates should induce both protective
cellular Th1 and humoral Th2 responses [46]. The im-
mune regulatory factors IFN-γ, IL-2 and IgG2a are associ-
ated with Th1-type responses, and IL-4, IL-10 and IgG1
are associated with Th2-type responses [47,48]. In this
study, mice immunized with the peptides exhibited a
mixed Th1/Th2 response with high titers of antigen-
specific IgG1 and IgG2a antibodies. Our results showed
that immunization with mixtures of A1 + R2 peptides
can enhance the Th1 or Th2 mediated immunity, as evi-
denced by high levels of IFN-γ, IL-2 or IL-4 compared
with the control group or single peptide groups. However,
the production of IL-10 was not statistically different be-
tween different groups (P >0.05). Thus IFN-γ-mediated
immune responses are necessary to control both the acute
and chronic phases of T. gondii infection [49,50]. IL-4 may
be involved in controlling T. gondii tachyzoites in the
brain [51].
During the evaluation of protection potency, the highly
virulent RH strain of T. gondii was used as the challen-
ging infection in this study. All mice immunized with
peptides showed significantly protective efficacy against
nonlethal T. gondii infection compared with the control
(P < 0.05). Furthermore, the mice immunized with A1 +
R2, AMA1, A1 + R2 + R4 and RON2 against lethal
T. gondii infection showed a significantly higher survival
rate (P < 0.05); in particular the mice immunized with
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loads in the liver (55.79%) and the brain (55.68%). These
results were consistent with previous reports that indi-
cated that a DNA vaccine expressing RON4 and recom-
binant protein RON4 vaccine failed to protect the mice
against oral challenge with T. gondii cysts [19].
A growing body of current research has focused on
cocktail or multi-antigenic vaccines [18,52]. The en-
hanced immune responses and protective efficacy in-
duced by mixtures of peptides in this study, especially
A1 + R2, coincide with the results of the above-described
studies, and the results also indicated that AMA1-RON2
interaction may play a key role in invasion by Toxo-
plasma gondii. This means that the combination of
AMA1 and RON2 would be a better solution to fight
against T. gondii induced immune reaction.
It is worth noting that the enhanced immune re-
sponses and protective efficacy induced by mixtures of
two peptides, especially AMA1 and RON2 mixture, were
more powerful and efficient than the mixture of three
peptides. What are the reasons leading to this result?
The analysis of the factors showed that the doses of mix-
ture of three peptides group (10 μg each peptide) were
less than doses of mixture of two peptides (15 μg each
peptide) and it suggests that when antigen dose is too
low, even if the three antigens are mixed, a better im-
mune effect is not achieved.
Conclusions
The intranasal immunization of mice with a single pep-
tide (AMA1, RON2, RON4) or a mixture of peptides
(A1 + R2, A1 + R4, R2 + R4 and A1 + R2 + R4) has been
shown to induce effective mucosal and systemic immune
responses and to elicit partial protection against acute
and chronic T. gondii infection. Moreover, our study in-
dicated that a mixture of peptides, especially the A1 + R2
mixture, was more powerful and efficient than a single
peptide. These results demonstrated that AMA1, RON2
and RON4 containing T- and B-cell epitopes can be
considered possible candidate antigens against toxoplas-
mosis, and a combination of peptides as a mucosal vac-
cine strategy is essential for future Toxoplasma vaccine
development.
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